Human Papillomavirus Genotype
Use
The APTIMA HPV 16 18/45 Genotype Assay is used for the qualitative detection of E6/E7 viral messenger RNA (mRNA) of HPV types 16, 18, and 45 in cervical specimens from women with positive APTIMA HPV Assay results. It can differentiate HPV 16 from HPV 18 and/or 45, providing useful information for assessing risk of cervical cancer progression.
Special Instructions
Final turnaround times may be specified differently in biopharma study contracts, as turnaround times listed are subject to change based on protocol requirements.
Limitations
The assay can differentiate HPV 16 from HPV 18 and/or HPV 45, but does not differentiate between HPV 18 and HPV 45. The results should be interpreted in conjunction with other clinical evaluations and diagnostic procedures.
Methodology
Other (Transcription-Mediated Amplification)
Biomarkers
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Cervical Swab
Volume
2 mL
Minimum Volume
Not provided
Container
ThinPrep® or SurePath™
Storage Instructions
2°C to 30°C
Causes for Rejection
Insufficient specimen; Low sample cellularity